Vivimed Labs Limited (VIVIMEDLAB)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 22 July 2026

₹7.39

🎯 Key Takeaways

Vivimed Labs Limited is currently in a severe financial and regulatory distress phase, marked by declining operational performance, persistent losses, and initiation of Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code. The company has not disclosed audited financial results in recent filings, and its voluntary delisting proposal suggests limited investor appetite and potential governance concerns.
Revenue grew 47.4% QoQ to ₹37 in Q3FY25.
⚠️ Ongoing Corporate Insolvency Resolution Process (CIRP) with high risk of liquidation or dilution of shareholder value.

Market Cap

₹61

P/E Ratio

-4.4

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About VIVIMEDLAB 📊 Interactive Charts

📖 The Story

Vivimed Labs Limited is currently in a severe financial and regulatory distress phase, marked by declining operational performance, persistent losses, and initiation of Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code. The company has not disclosed audited financial results in recent filings, and its voluntary delisting proposal suggests limited investor appetite and potential governance concerns. With negative EBITDA trends, deteriorating margins, and mounting operational challenges, the company appears to be in a turnaround or restructuring phase with uncertain recovery prospects.

📰 What's Happening

The most critical development is the initiation of CIRP by the NCLT Bengaluru Bench on April 15, 2026, formally admitted on June 17, 2026, with a resolution deadline set for October 11, 2026. This follows a prior admission of insolvency proceedings on April 23, 2026, indicating escalating financial stress. The company attempted to publish FY2026 audited results on July 22, 2026, but the filing avoided financial metrics, focusing instead on procedural updates like delisting and postal ballot. Earlier, on May 30, 2026, a board meeting to approve results was postponed without disclosure of performance data. Additionally, a technical delay in filing FY2025 results due to XBRL and signature issues on June 25, 2026, further undermined credibility. These events reflect governance instability and an inability to communicate transparent financial updates.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	37	35	34	41	39	29	25	37
Operating Profit	-164	-0	-4	1	-21	-4	-1	1
OPM %	-443.7%	-0.9%	-17.6%	3.1%	-73.7%	-13.4%	-2.6%	2.9%
Net Profit	-266	-16	-20	-16	5	-8	-5	-6
EPS	₹-32.08	₹1.88	₹-2.45	₹-1.24	₹0.64	₹-0.99	₹-0.60	₹-0.72

Revenue has shown volatility but no sustainable recovery, declining 15.6% YoY in Q3FY25 to ₹37 Cr from ₹41 Cr in Q3FY24, with operating profit margin improving from -73.7% in Q4FY24 to 2.9% in Q3FY25, suggesting marginal cost control but not profitability. However, this improvement is from a deeply loss-making base, and operating profit remains fragile. Net loss narrowed slightly to ₹-6 Cr in Q3FY25 from ₹-5 Cr in Q2FY25, but cumulative losses persist. The company posted a rare profit of ₹5 Cr in Q4FY24, but this was an outlier amid otherwise consistent losses. The absence of disclosed financials in recent filings, coupled with a negative operating margin trend over multiple quarters, indicates structural profitability challenges. The lack of transparent performance reporting severely limits visibility into financial health.

🔮 Management Outlook & What's Next

Management has not provided forward-looking guidance or strategic commentary in recent filings, particularly in the absence of disclosed financial results. The company’s focus has been on procedural compliance, delisting, and insolvency process navigation rather than growth or recovery planning. There is no public statement from management outlining a recovery strategy, capital restructuring, or operational turnaround plan. The repeated delays and technical issues in filing suggest operational disarray, and without disclosed metrics or commentary, the management’s outlook remains opaque and uncommunicated.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1. Ongoing Corporate Insolvency Resolution Process (CIRP) with high risk of liquidation or dilution of shareholder value. 2. Persistent financial losses and negative operating margins despite marginal improvements, with no sustainable profitability in sight. 3. Repeated delays and technical issues in financial filings, undermining credibility and transparency. 4. Lack of disclosed financial metrics in key announcements, making performance assessment nearly impossible. 5. Voluntary delisting proposal, which may signal promoter exit or inability to meet exchange listing standards. These factors collectively indicate severe governance, financial, and structural risks.

📋 Recent Filings

🧠 Analyst's Read

Vivimed Labs is in a critical phase marked by insolvency proceedings, financial instability, and eroding transparency, with no clear path to recovery or operational revival. Investors should monitor developments in the CIRP process, potential resolution plans, and any future disclosure of audited financials. The company’s ability to stabilize operations or attract resolution applicants will determine the ultimate outcome for shareholders, which currently appears highly uncertain and risky.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on VIVIMEDLAB

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-22.

📡 Get AI alerts when VIVIMEDLAB files new disclosures

Track VIVIMEDLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track VIVIMEDLAB — Free

Free account · 2 AI queries/day